Evidence map›Paper›PMID 33247586›Full record

ReviewJournal of travel medicine2020

GeoSentinel: past, present and future†.

Davidson H Hamer, Aisha Rizwan, David O Freedman, Phyllis Kozarsky, Michael Libman

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of travel medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Cutaneous larva migrans in Canadian travellers returning from the Caribbean: A 10-year surveillance analysis from CanTravNet.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Travel-Related Diagnoses Among U.S. Nonmigrant Travelers or Migrants Presenting to U.S. GeoSentinel Sites - GeoSentinel Network, 2012-2021.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. West Nile virus: another emerging arboviral risk for travelers?Current infectious disease reports · 2022
    Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Davidson H HamerDepartment of Global Health, Boston University School of Public Health, Crosstown 308, 801 Massachusetts Avenue, Boston, MA 02118, USA.
Aisha RizwanGeoSentinel, International Society of Travel Medicine, 11720 Amber Park Drive, Suite 160, Alpharetta, GA 30009, USA.
David O FreedmanDivision of Infectious Diseases, University of Alabama at Birmingham, 1720 2nd Ave S, BBRB 201, Birmingham, AL 35294 2170, USA.
Phyllis KozarskyDivision of Infectious Diseases (Emerita), Department of Medicine, Emory University, 2500 Peachtree Road NW, Suite 505, Atlanta, GA 30305, USA.
Michael LibmanJ.D. MacLean Centre for Tropical Diseases, McGill University, Room E05.1830, 1001 Boulevard Décarie, Montréal, Québec H4A 3J1, Canada.
Boston University · USEmory University · USInternational Society of Travel Medicine · USMcGill University · CAUniversity of Alabama at Birmingham · US

Funding

NCEZID CDC HHS U38 CK000478NCEZID CDC HHS U50 CK000189
6 · The paper itself

Abstract

rationale for reviewIn response to increased concerns about emerging infectious diseases, GeoSentinel, the Global Surveillance Network of the International Society of Travel Medicine in partnership with the US Centers for Disease Control and Prevention (CDC), was established in 1995 in order to serve as a global provider-based emerging infections sentinel network, conduct surveillance for travel-related infections and communicate and assist global public health responses. This review summarizes the history, past achievements and future directions of the GeoSentinel Network. KEY

findingsFunded by the US CDC in 1996, GeoSentinel has grown from a group of eight US-based travel and tropical medicine centers to a global network, which currently consists of 68 sites in 28 countries. GeoSentinel has provided important contributions that have enhanced the ability to use destination-specific differences to guide diagnosis and treatment of returning travelers, migrants and refugees. During the last two decades, GeoSentinel has identified a number of sentinel infectious disease events including previously unrecognized outbreaks and occurrence of diseases in locations thought not to harbor certain infectious agents. GeoSentinel has also provided useful insight into illnesses affecting different traveling populations such as migrants, business travelers and students, while characterizing in greater detail the epidemiology of infectious diseases such as typhoid fever, leishmaniasis and Zika virus disease.

conclusionsSurveillance of travel- and migration-related infectious diseases has been the main focus of GeoSentinel for the last 25 years. However, GeoSentinel is now evolving into a network that will conduct both research and surveillance. The large number of participating sites and excellent geographic coverage for identification of both common and illnesses in individuals who have traversed international borders uniquely position GeoSentinel to make important contributions of travel-related infectious diseases in the years to come.

Indexed as

COVID-19International CooperationSentinel SurveillanceTravel MedicineCenters for Disease Control and Prevention, U.S.Geographic Information SystemsHumansSARS-CoV-2Travel-Related IllnessUnited Statesantimicrobial resistanceCOVID-19emerging infectious diseasesSentinel eventsurveillancetravel medicineZika

Identifiers

PMID33247586
PMCPMC7799014
OpenAlexW3107897787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.